Your browser is no longer supported. Please, upgrade your browser.
Settings
NVAX [NASD]
Novavax, Inc.
Index- P/E- EPS (ttm)-9.25 Insider Own0.20% Shs Outstand73.03M Perf Week14.57%
Market Cap15.19B Forward P/E6.94 EPS next Y30.21 Insider Trans-47.52% Shs Float69.32M Perf Month64.04%
Income-615.10M PEG- EPS next Q-3.63 Inst Own58.20% Short Float8.38% Perf Quarter3.41%
Sales919.50M P/S16.51 EPS this Y-32.00% Inst Trans9.97% Short Ratio1.64 Perf Half Y81.98%
Book/sh14.23 P/B14.74 EPS next Y603.40% ROA-40.60% Target Price258.00 Perf Year371.93%
Cash/sh27.59 P/C7.60 EPS next 5Y0.00% ROE-125.70% 52W Range43.60 - 331.68 Perf YTD88.04%
Dividend- P/FCF26.39 EPS past 5Y9.50% ROI-38.00% 52W High-37.52% Beta1.56
Dividend %- Quick Ratio1.90 Sales past 5Y67.30% Gross Margin- 52W Low375.28% ATR14.94
Employees791 Current Ratio1.90 Sales Q/Q3072.20% Oper. Margin-65.50% RSI (14)65.03 Volatility7.79% 8.26%
OptionableYes Debt/Eq0.44 EPS Q/Q-423.70% Profit Margin-66.90% Rel Volume3.51 Prev Close209.68
ShortableYes LT Debt/Eq0.33 EarningsMay 10 AMC Payout- Avg Volume3.54M Price207.22
Recom2.20 SMA2026.27% SMA5014.46% SMA20035.24% Volume9,778,979 Change-1.17%
May-12-21Downgrade JP Morgan Overweight → Neutral $285 → $161
Dec-14-20Initiated Jefferies Buy $200
Aug-06-20Reiterated H.C. Wainwright Buy $132 → $290
Aug-05-20Upgrade JP Morgan Neutral → Overweight $275
Aug-05-20Downgrade Ladenburg Thalmann Neutral → Sell $105
Jul-16-20Reiterated H.C. Wainwright Buy $101 → $132
Jul-08-20Downgrade Ladenburg Thalmann Buy → Neutral $50 → $105
Jun-29-20Reiterated H.C. Wainwright Buy $50 → $101
Jun-29-20Reiterated B. Riley FBR Buy $74 → $106
Jun-05-20Upgrade JP Morgan Underweight → Neutral $46
May-28-20Reiterated B. Riley FBR Buy $53 → $61
May-12-20Reiterated H.C. Wainwright Buy $33 → $50
Apr-30-20Reiterated H.C. Wainwright Buy $24 → $33
Nov-27-19Resumed B. Riley FBR Buy $12
Aug-14-19Reiterated H.C. Wainwright Buy $10 → $17
Feb-28-19Downgrade Piper Jaffray Overweight → Underweight $4.50 → $0.25
Dec-18-18Initiated Ladenburg Thalmann Buy $3
Dec-11-18Initiated Oppenheimer Outperform $4
Nov-26-18Upgrade Piper Jaffray Neutral → Overweight
Sep-21-18Upgrade JP Morgan Underweight → Overweight
Jun-14-21 01:47PM  
01:27PM  
01:01PM  
12:56PM  
12:04PM  
11:45AM  
11:03AM  
10:56AM  
10:55AM  
09:56AM  
09:56AM  
09:53AM  
08:54AM  
08:11AM  
08:02AM  
07:35AM  
07:00AM  
06:44AM  
06:40AM  
06:29AM  
06:12AM  
06:05AM  
06:00AM  
06:00AM  
04:36AM  
02:34AM  
02:20AM  
Jun-13-21 08:00PM  
Jun-12-21 06:08AM  
Jun-11-21 05:37PM  
04:05PM  
Jun-10-21 12:07PM  
06:06AM  
Jun-09-21 02:50PM  
11:30AM  
09:03AM  
Jun-08-21 06:40PM  
02:03PM  
10:30AM  
Jun-07-21 04:05PM  
03:13PM  
02:33PM  
01:45PM  
Jun-06-21 03:04PM  
Jun-05-21 07:31AM  
Jun-04-21 03:53PM  
03:20PM  
02:50PM  
02:12PM  
09:38AM  
Jun-03-21 01:36PM  
11:30AM  
09:36AM  
06:06AM  
Jun-02-21 04:10PM  
02:15PM  
09:41AM  
Jun-01-21 02:57PM  
03:46AM  
May-31-21 06:01AM  
May-29-21 06:42AM  
May-28-21 01:43PM  
07:03AM  
May-27-21 02:10PM  
08:30AM  
May-26-21 02:52PM  
02:05PM  
02:03PM  
May-25-21 03:13PM  
02:44PM  
01:53PM  
11:30AM  
05:51AM  
May-24-21 05:03PM  
02:28PM  
01:51PM  
12:13PM  
May-23-21 06:04AM  
May-22-21 12:39PM  
12:20PM  
11:31AM  
07:01AM  
06:13AM  
May-21-21 01:43PM  
08:53AM  
May-20-21 01:58PM  
10:47AM  
05:04AM  
02:11AM  
02:00AM  
May-19-21 01:49PM  
May-18-21 06:00AM  
05:21AM  
May-17-21 07:43AM  
06:06AM  
May-16-21 11:09PM  
May-15-21 06:06AM  
06:02AM  
May-14-21 05:27PM  
04:06PM  
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. In addition, the company develops vaccine candidates for the protection against middle east respiratory syndrome, as well as that is in preclinical work associated with severe acute respiratory syndrome; and ebola virus glycoprotein vaccine candidate, as well as COVID-19 vaccine for variant strain. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
EVANS GARY CDirectorJun 01Sale146.5062591,5620Jun 03 05:34 PM
Herrmann John A IIIEVP, Chief Legal OfficerMay 28Option Exercise14.832,89542,9323,170Jun 02 04:59 PM
Herrmann John A IIIEVP, Chief Legal OfficerMay 28Sale149.142,895431,748275Jun 02 04:59 PM
King Rachel K.DirectorMay 19Buy139.6470097,7482,800May 21 05:06 PM
Glenn Gregory MPresident, R&DMay 19Sale142.172,385339,0662,811May 19 05:26 PM
Glenn Gregory MPresident, R&DMay 17Option Exercise13.1610,531138,5778,523May 19 05:26 PM
Glenn Gregory MPresident, R&DMay 17Sale133.985,712765,2672,811May 19 05:26 PM
Trizzino JohnEVP, CCO, CBO & Interim CFOMay 07Sale176.6319033,559287May 07 05:10 PM
Trizzino JohnEVP, CCO, CBO & Interim CFOMay 05Option Exercise14.733,40650,1603,309May 07 05:10 PM
Trizzino JohnEVP, CCO, CBO & Interim CFOMay 05Sale185.463,022560,471287May 07 05:10 PM
Herrmann John A IIIEVP, Chief Legal OfficerApr 30Option Exercise14.822,89542,8923,170May 04 06:03 PM
Herrmann John A IIIEVP, Chief Legal OfficerApr 30Sale239.832,895694,317275May 04 06:03 PM
Trizzino JohnEVP, Chief Commercial OfficerApr 07Sale178.0319134,004287Apr 07 05:09 PM
Trizzino JohnEVP, Chief Commercial OfficerApr 05Option Exercise34.013,404115,7713,308Apr 07 05:09 PM
Trizzino JohnEVP, Chief Commercial OfficerApr 05Sale190.103,021574,292287Apr 07 05:09 PM
Herrmann John A IIIEVP, Chief Legal OfficerMar 26Option Exercise14.822,89442,8863,169Mar 30 06:10 PM
Herrmann John A IIIEVP, Chief Legal OfficerMar 26Sale186.802,894540,609275Mar 30 06:10 PM
YOUNG JAMES FDirectorMar 25Option Exercise8.9647,500425,43857,500Mar 25 06:41 PM
YOUNG JAMES FDirectorMar 23Option Exercise46.0010,000460,00020,000Mar 25 06:41 PM
YOUNG JAMES FDirectorMar 23Sale228.2210,0002,282,23110,000Mar 25 06:41 PM
MCMANUS MICHAEL A JRDirectorMar 19Sale220.784,000883,1105,951Mar 23 05:33 PM
Glenn Gregory MPresident, R&DMar 17Sale218.862,423530,3042,811Mar 17 06:35 PM
Glenn Gregory MPresident, R&DMar 15Option Exercise109.9510,5311,157,8438,523Mar 17 06:35 PM
EVANS GARY CDirectorMar 15Option Exercise19.5224,500478,33040,599Mar 17 06:36 PM
EVANS GARY CDirectorMar 15Sale211.2124,5005,174,53616,099Mar 17 06:36 PM
Glenn Gregory MPresident, R&DMar 15Sale198.605,7121,134,4002,811Mar 17 06:35 PM
Trizzino JohnEVP, Chief Commercial OfficerMar 09Sale168.0919031,937287Mar 09 07:38 PM
Trizzino JohnEVP, Chief Commercial OfficerMar 05Option Exercise14.733,40450,1483,308Mar 09 07:38 PM
Trizzino JohnEVP, Chief Commercial OfficerMar 05Sale163.463,021493,824287Mar 09 07:38 PM
Herrmann John A IIIEVP, Chief Legal OfficerFeb 26Option Exercise14.822,89542,8923,170Mar 02 05:37 PM
Herrmann John A IIIEVP, Chief Legal OfficerFeb 26Sale225.482,895652,759275Mar 02 05:37 PM
Glenn Gregory MPresident, R&DFeb 18Sale269.572,434656,1342,811Feb 18 06:59 PM
Glenn Gregory MPresident, R&DFeb 16Option Exercise13.1610,531138,5778,523Feb 18 06:55 PM
Glenn Gregory MPresident, R&DFeb 16Sale282.715,7121,614,8122,811Feb 18 06:55 PM
Trizzino JohnEVP, Chief Commercial OfficerFeb 09Sale324.5019462,953287Feb 09 07:40 PM
Trizzino JohnEVP, Chief Commercial OfficerFeb 05Option Exercise14.733,40650,1603,309Feb 09 07:40 PM
Trizzino JohnEVP, Chief Commercial OfficerFeb 05Sale290.463,022877,766287Feb 09 07:40 PM
Herrmann John A IIIEVP, Chief Legal OfficerFeb 01Option Exercise18.1515,022272,72415,297Feb 03 05:37 PM
Herrmann John A IIIEVP, Chief Legal OfficerFeb 01Sale241.5015,0223,627,789275Feb 03 05:37 PM
Trizzino JohnEVP, CMO and CBOJan 07Sale124.1750662,830287Jan 07 07:08 PM
Trizzino JohnEVP, CMO and CBOJan 05Option Exercise18.6313,756256,24317,694Jan 07 07:08 PM
Trizzino JohnEVP, CMO and CBOJan 05Sale112.0017,4071,949,522287Jan 07 07:08 PM
YOUNG JAMES FDirectorDec 31Option Exercise51.2711,000564,00011,000Jan 05 05:38 PM
DOUGLAS RICHARDDirectorDec 31Option Exercise50.001,00050,00028,500Jan 05 05:42 PM
YOUNG JAMES FDirectorDec 31Sale113.0911,0001,244,0140Jan 05 05:38 PM
Erck Stanley CPresident and CEONov 16Option Exercise37.1452,3171,942,80172,811Nov 18 06:09 PM
Erck Stanley CPresident and CEONov 16Sale90.6552,3164,742,66720,495Nov 18 06:09 PM
Erck Stanley CPresident and CEOOct 01Sale108.56221720,494Oct 01 05:39 PM
Trizzino JohnEVP, CBO and CFOSep 30Sale110.222,250248,0025,087Oct 01 05:40 PM
Erck Stanley CPresident and CEOSep 30Sale110.2312,2311,348,20020,496Oct 01 05:39 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 29Sale107.3118,0291,934,667275Sep 30 09:30 PM
Glenn Gregory MPresident, R&DSep 29Sale107.0219,9492,134,8441,561Sep 30 09:29 PM
Trizzino JohnEVP, CBO and CFOSep 29Sale107.2918,3211,965,6307,337Sep 30 09:28 PM
Erck Stanley CPresident and CEOSep 29Sale107.804,112443,26732,727Sep 30 09:27 PM
Erck Stanley CPresident and CEOSep 28Option Exercise5.9550,000297,50074,606Sep 30 09:27 PM
Trizzino JohnEVP, CBO and CFOSep 28Option Exercise5.9529,600176,12053,008Sep 30 09:28 PM
Glenn Gregory MPresident, R&DSep 28Option Exercise5.9525,000148,75046,510Sep 30 09:29 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 28Option Exercise5.9524,750147,26243,054Sep 30 09:30 PM
Glenn Gregory MPresident, R&DSep 28Sale110.3025,0002,757,45621,510Sep 30 09:29 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 28Sale110.3024,7502,729,87918,304Sep 30 09:30 PM
Trizzino JohnEVP, CBO and CFOSep 28Sale110.3025,0002,757,45625,658Sep 30 09:28 PM
Erck Stanley CPresident and CEOSep 28Sale110.3025,0002,757,45636,839Sep 30 09:27 PM
EVANS GARY CDirectorAug 18Option Exercise31.0210,500325,700332,479Aug 20 06:09 PM
Glenn Gregory MPresident, R&DAug 18Option Exercise33.5655,9211,876,52557,760Aug 20 06:14 PM
Herrmann John A IIIEVP, Chief Legal OfficerAug 18Option Exercise53.8246,2422,488,61346,517Aug 20 06:20 PM
MCMANUS MICHAEL A JRDirectorAug 18Option Exercise27.608,000220,80017,951Aug 20 06:22 PM
Trizzino JohnEVP, CBO and CFOAug 18Option Exercise50.9542,7882,179,98647,875Aug 20 06:25 PM
Trizzino JohnEVP, CBO and CFOAug 18Sale148.7842,7886,366,1825,087Aug 20 06:25 PM
MCMANUS MICHAEL A JRDirectorAug 18Sale146.008,0001,168,0009,951Aug 20 06:22 PM
Herrmann John A IIIEVP, Chief Legal OfficerAug 18Sale144.3346,2426,673,982275Aug 20 06:20 PM
Glenn Gregory MPresident, R&DAug 18Sale145.2055,9218,119,8601,839Aug 20 06:14 PM
EVANS GARY CDirectorAug 18Sale150.4410,5001,579,620321,979Aug 20 06:09 PM
Glenn Gregory MPresident, R&DJun 18Option Exercise42.2016,749706,80818,588Jun 22 05:29 PM
Glenn Gregory MPresident, R&DJun 18Sale59.5316,749997,1031,839Jun 22 05:29 PM